Transfusion Medicine Reviews
Volume 21, Issue 1 , Pages 37-48, January 2007

Anticoagulants and Their Reversal

  • Sam Schulman

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Sam Schulman, MD Thrombosis Service HHS-General Hospital 237 Barton Street East Hamilton, ON, Canada L8L 2X2.
  • ,
  • Nick R. Bijsterveld

Department of Medicine, McMaster University, Hamilton, ON, Canada

Department of Cardiology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

In an exciting era with many alternatives to the old anticoagulants heparin and warfarin emerging on the scene, awareness of the possibility to reverse their effect is mandatory. In this review, the traditional antidotes for warfarin (vitamin K, plasma, and prothrombin complex concentrate) and for heparin (protamine) are described together with the newer alternatives (recombinant activated factor VII, concatameric peptides, and recombinant platelet factor 4). For some of the newer anticoagulants, possible antidotes have been identified, whereas other alternatives have been discarded. There is a very limited experience of deamino-d-arginine vasopressin or a von Willebrand factor VIII concentrate to counteract hirudin. The small direct thrombin inhibitors may be reversed with activated prothrombin complex concentrate but not with recombinant activated factor VII, whereas the latter agent appears to be effective against the pentasaccharides and the recombinant nematode anticoagulant protein C2. Additional options that may become available in the future are also discussed briefly.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0887-7963(06)00059-9

doi:10.1016/j.tmrv.2006.08.002

Transfusion Medicine Reviews
Volume 21, Issue 1 , Pages 37-48, January 2007